Despite decades of global health investment, diarrhoeal and enteric diseases remain a leading killer of young children — and a comprehensive new dataset now reveals precisely where progress has stalled and why the 2025 mortality target may be out of reach for many nations. The findings reframe the challenge from a resource problem to a geographic and epidemiological targeting problem.
Drawing on the Global Burden of Disease Study 2023 framework, this systematic analysis quantified incidence, mortality, and disability-adjusted life-years (DALYs) across 204 countries and territories over a 33-year span from 1990 to 2023. The scope is exceptional: 15 distinct diarrhoeal aetiologies were disaggregated, alongside enteric fever (typhoid and paratyphoid), invasive non-typhoidal Salmonella (iNTS), and other intestinal infections. Using DisMod-MR 2.1, a Bayesian meta-regression tool integrating systematic reviews, population surveys, claims data, and hospital records, the researchers generated age- and sex-stratified burden estimates with unprecedented granularity. While overall global mortality has declined substantially since 1990, the pace of reduction has decelerated in sub-Saharan Africa and parts of South Asia, where under-five death rates remain far above the Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD) target of fewer than 20 deaths per 100,000 children by 2025.
This analysis is among the most methodologically rigorous attempts to map enteric disease burden globally, and its significance extends beyond headline mortality figures. The pathogen-level disaggregation — distinguishing rotavirus, Cryptosporidium, enterotoxigenic E. coli, Shigella, and others — enables targeted vaccine and intervention prioritization in a way aggregate data cannot. Rotavirus vaccine scale-up has clearly bent the mortality curve in some regions, but iNTS and Shigella burdens remain underappreciated and underfunded. A key limitation is data sparsity in the highest-burden settings, where the Bayesian modeling fills genuine epidemiological gaps with uncertainty intervals that merit caution. This is confirmatory and expansive rather than paradigm-shifting, but its policy utility is high: health systems allocating WASH infrastructure, oral rehydration therapy, and vaccination programs now have a granular, updated roadmap for where marginal investment yields the greatest child survival returns.